Arrowstreet Capital
ODT

Arrowstreet Capital’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Arrowstreet Capital’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-109,299
Closed -$2.1M – 2660
2020
Q4 		$2.1M Sell
109,299
-15,914
-13% -$246K ﹤0.01% 1579
2020
Q3 		$1.68M Buy
125,213
+118,893
+1,881% +$3.37M ﹤0.01% 1631
2020
Q2 		$268K Buy
+6,320
New +$205K ﹤0.01% 2129
2020
Q1 		– Sell
-10,400
Closed -$337K – 2216
2019
Q4 		$337K Buy
+10,400
New +$322K ﹤0.01% 1552

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Arrowstreet Capital's ODT Position: Q1 2021 in Review

Arrowstreet Capital sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2021, closing a stake of 109,299 shares — an estimated $2.1M sold.

Arrowstreet Capital first reported a position in ODT in Q4 2019 and held it in 4 quarters. The position peaked at $2.1M in Q4 2020. 83 funds tracked by Wall St. Rank hold ODT as of Q1 2021.

  • Arrowstreet Capital reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 109,299 Odonate Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $2.1M.
  • Arrowstreet Capital first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Odonate Therapeutics, Inc. Common Stock position peaked at $2.1M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.